NatImmune's Other Investors

NatImmune raised a round of funding on , . Investors include Novo A/S.

NatImmune A/S has developed a product for replacement therapy of Mannan Binding Lectin (MBL) in patients carrying genetic pre-disposition to infections through a deficiency in the immune system. The p…

Articles about NatImmune's Other Investors: